Association of Changes in Macular Perfusion With Ranibizumab Treatment for Diabetic Macular Edema: A Subanalysis of the RESTORE (Extension) Study

COMMENTED

Macular Diseases

Association Between Change in Visual Acuity and Change in Central Subfield Thickness During Treatment of Diabetic Macular Edema in Participants Randomized to Aflibercept, Bevacizumab, or Ranibizumab: A Post Hoc Analysis of the Protocol T Randomized Clinical Trial

JAMA Ophthalmol.

Bressler NM, Odia I, Maguire M, Glassman AR, Jampol LM, MacCumber MW, Shah C, Rosberger D, Sun JK, DRCR Retina Network.

doi: 10.1001/jamaophthalmol.

Macular Diseases

Longitudinal Retinal Perfusion Status in Eyes with Diabetic Macular Edema Receiving Intravitreal Aflibercept or Laser in VISTA study

Ophthalmology.

Wykoff CC, Shah C, Dhoot D, Coleman HR, Thompson D, Du W, Baker K, Vitti R, Berliner AJ, Metzig C, Saroj N

doi: 10.1016/j.ophtha.

COMMENTED

Macular Diseases

Five-Year Outcomes after Initial Aflibercept, Bevacizumab, or Ranibizumab Treatment for Diabetic Macular Edema (Protocol T Extension Study)

doi: 10.1016/j.ophtha.2020.03.021.

Macular Diseases

Ranibizumab for the Treatment of Diabetic Macular Oedema in the Real-World Clinical Setting in Portugal: A Multicentre Study

Ophthalmologica.

Farinha C, Martins A, Neves A, Soares R, Ruão M, Ornelas M, Neves P, Gomes Rodrigues F, Coelho C, Silva R

doi: 10.1159/000489046.

Macular DiseasesRetinal Diseases

PREDICTIVE VALUE OF OPTICAL COHERENCE TOMOGRAPHIC FEATURES IN THE BEVACIZUMAB AND RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA (BRDME) STUDY

Retina.

Fickweiler W, Schauwvlieghe AM, Schlingemann RO, Maria Hooymans JM, Los LI, Verbraak FD; BRDME Research Group

doi: 10.1097/IAE.

Macular DiseasesRetinal Diseases

A noninterventional study to monitor patients with diabetic macular oedema starting treatment with ranibizumab (POLARIS)

Acta Ophthalmol.

Stefanickova J, Cunha-Vaz J, Ulbig M, Pearce I, Fernández-Vega Sanz A, Theodossiadis P, Kodjikian L, Izmailov A, Muston D, Vassilev Z, Lamotte B, Tückmantel C, Friedl S, Altemark A, Schwarz HJ, Katz T; POLARIS study investigators

doi: 10.1111/aos.13771.

Macular Diseases

Factors Associated With Visual Acuity and Central Subfield Thickness Changes When Treating Diabetic Macular Edema With Anti-Vascular Endothelial Growth Factor Therapy: An Exploratory Analysis of the Protocol T Randomized Clinical Trial

JAMA Ophthalmol.

Bressler SB, Odia I, Maguire MG, Dhoot DS, Glassman AR, Jampol LM, Marcus DM, Solomon SD, Sun JK; Diabetic Retinopathy Clinical Research Network

doi: 10.1001/jamaophthalmol.

Macular Diseases

PRAGMATISM OF RANDOMIZED CLINICAL TRIALS ON RANIBIZUMAB FOR THE TREATMENT OF DIABETIC MACULAR EDEMA

Retina.

Stewart S, Yeong JL, Virgili G, Azuara-Blanco A, Lois N

doi: 10.1097/IAE.0000000000002476.

RECOMMENDED

Retinal DiseasesSurgery and Intervention

Durability of Diabetic Retinopathy Improvement with As-Needed Ranibizumab: Open-label Extension of RIDE and RISE Studies

Ophthalmology.

Sun JK, Wang PW, Taylor S, Haskova Z

doi: 10.1016/j.ophtha.2018.10.041.

Related content

Association Between Change in Visual Acuity and Change in Central Subfield Thickness During Treatment of Diabetic Macular Edema in Participants Randomized to Aflibercept, Bevacizumab, or Ranibizumab: A Post Hoc Analysis of the Protocol T Randomized Clinical Trial

Longitudinal Retinal Perfusion Status in Eyes with Diabetic Macular Edema Receiving Intravitreal Aflibercept or Laser in VISTA study

Five-Year Outcomes after Initial Aflibercept, Bevacizumab, or Ranibizumab Treatment for Diabetic Macular Edema (Protocol T Extension Study)

Ranibizumab for the Treatment of Diabetic Macular Oedema in the Real-World Clinical Setting in Portugal: A Multicentre Study

PREDICTIVE VALUE OF OPTICAL COHERENCE TOMOGRAPHIC FEATURES IN THE BEVACIZUMAB AND RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA (BRDME) STUDY

A noninterventional study to monitor patients with diabetic macular oedema starting treatment with ranibizumab (POLARIS)

Factors Associated With Visual Acuity and Central Subfield Thickness Changes When Treating Diabetic Macular Edema With Anti-Vascular Endothelial Growth Factor Therapy: An Exploratory Analysis of the Protocol T Randomized Clinical Trial

PRAGMATISM OF RANDOMIZED CLINICAL TRIALS ON RANIBIZUMAB FOR THE TREATMENT OF DIABETIC MACULAR EDEMA

Durability of Diabetic Retinopathy Improvement with As-Needed Ranibizumab: Open-label Extension of RIDE and RISE Studies